This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • World Health  • HIV/AIDS  • Alert me on articles by topic

Joan Stephenson, PhD

JAMA. 2004;291:1431-1433.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Francisco—Resistance to drugs used in simplified drug regimens designed to prevent or treat HIV infection is complicating efforts to fight the AIDS epidemic, according to new findings reported here at the 11th Annual Retrovirus Conference.

In addition, researchers described other work highlighting the importance of tracking HIV infection in the United States to identify opportunities for focused prevention efforts.

MOTHER-TO-CHILD TRANSMISSION

A drug regimen used in resource-poor countries to prevent mother-to-child HIV transmission might compromise a mother's response to future treatment because it may promote drug resistance, according to findings of studies in South Africa and Thailand.

Providing a single dose of nevirapine during labor to the mother and a single dose to the newborn during the first 3 days after delivery has been a prevention cornerstone for reducing mother-to-child transmission in developing countries from about 30% to about 15%. Although other regimens may be . . . [Full Text of this Article]